BIOHAVEN LTD (BHVN)
VGG1110E1079 - Common Stock
BHVN January 2027 Options Begin Trading
Investors Pick Up BHVN Even Cheaper Than Its Secondary Stock Offering
Notable Wednesday Option Activity: PANW, BHVN, JACK
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial...
Notable Friday Option Activity: BHVN, GETY, AFRM
Top Buys by Directors: Childs's $1000K Bet on BHVN
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.
Biohaven Larger Than S&P 500 Component Deckers Outdoor
Noteworthy Thursday Option Activity: U, BHVN, RKT
Top Buys by Top Brass: Chief Executive Officer Coric's $1000K Bet on BHVN
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Announces Proposed Public Offering of Common Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally...
Wednesday 9/25 Insider Buying Report: PMN, BHVN
BHVN Crosses Above Key Moving Average Level
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
The company is hoping to soon file for approval of what could be the first SCA treatment.
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale...
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE...
Notable Thursday Option Activity: NOV, BHVN, SIG
Interesting BHVN Put And Call Options For December 20th
Biohaven Breaks Above 200-Day Moving Average - Bullish for BHVN
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024.
BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biohaven (NYSE:BHVN) just reported results for the second quarter of 2024.Bioha...
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of...
Biohaven(BHVN) Shares Cross Above 200 DMA
Investors Grab BHVN 14.9% Cheaper Than Its Secondary Stock Offering